Study to assess the efficacy, safety, and tolerability of AZD8529 in adult schizophrenia patients

Study identifier:D1960C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase IIa, Double-blind, Double-Dummy, Placebo-controlled, Active-controlled, Randomized, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of AZD8529 in Adult Schizophrenia Patients

Medical condition

schizophrenia

Phase

Phase 2

Healthy volunteers

No

Study drug

AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone

Sex

All

Actual Enrollment

152

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Jun 2009
Primary Completion Date: 01 May 2010
Study Completion Date: 01 May 2010

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2010 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria